Objective: Therapeutic anticoagulation (AC) is used clinically for prolongation of infrainguinal bypass patency, but evidence for the efficacy of this practice is conflicting. The objective of our study was to determine the association of AC with bypass graft primary patency.
Despite the proliferation and continual improvement of minimally invasive endovascular techniques, open surgical bypass is still required in many patients with peripheral arterial occlusive disease. 1, 2 Oral anticoagulation (AC) therapy has been used to improve the patency and durability of bypass grafts; however, the efficacy of AC for this purpose has not been clearly demonstrated in the literature because of conflicting results and variability of study methodology. [3] [4] [5] The efficacy of AC on bypass graft patency outside of trial settings has also not been extensively studied. The objective of this study was therefore to evaluate the association of AC therapy with infrainguinal bypass to a below-knee target using a large national disease-and procedurespecific data set.
METHODS
This study of deidentified national registry data was exempted from informed consent and approved by our Institutional Review Board and the Society for Vascular Surgery Patient Safety Organization Research Advisory Committee before data analysis.
Data from 2003 to 2014 were obtained from the Vascular Quality Initiative (VQI) infrainguinal bypass registry deidentified data set. Patients who underwent lower extremity infrainguinal bypass to a below-knee target were identified for inclusion in the study. Those without follow-up examinations were excluded. In addition to general demographic information, procedure-and diseasespecific information was obtained, including preoperative ambulatory status, preoperative use of AC and other relevant medications, previous ipsilateral surgical or interventional history, indication for procedure, and operative details including conduit type and use of operative adjuncts such as vein cuffs. Conduit type was categorized broadly as single-segment leg or arm vein or non-singlesegment vein (NSV) as single-segment vein conduits have demonstrated superiority compared with nonsingle-segment conduits. 6 The NSV category was further divided into prosthetic and spliced vein conduit types. The primary comparison groups were those receiving AC on discharge, defined as a vitamin K antagonist, direct thrombin inhibitor, or factor Xa inhibitor, and those discharged without anticoagulant therapy (non-AC).
The primary outcome was primary patency as documented in the VQI, determined by need for reintervention, graft thrombosis, or significant stenosis by duplex ultrasound imaging. The major secondary end points were secondary patency (failure of which was defined as graft occlusion without successful revision) and amputation-free survival. All long-term outcomes were defined on the basis of the Society for Vascular Surgery reporting guidelines for lower extremity ischemia.
1 Additional secondary outcomes included perioperative complications, which were analyzed using the total cohort. We accounted for the anticipated baseline and operative differences between groups by using propensity methods 7, 8 ; an inverse propensity-weighted analysis was used to balance clinical, operative, and comorbid characteristics between the AC and non-AC groups and to determine the average treatment effect of AC while preserving the use of the full range of data. A propensity score was derived from a logistic regression model fit on the likelihood of receiving AC, and the data were weighted according to the inverse propensity of receiving treatment (Supplementary Table I , online only). Propensity variables were chosen on the basis of clinical relevance and with significant differences on pairwise testing. Covariate balance in the weighted cohorts was assessed using standardized differences ( Supplementary Fig 1, online only) . 9 The comparability of the two cohorts was assessed by plotting the distribution of propensity scores ( Supplementary Fig 2, online only), showing few outliers and a large region of overlap between the two groups. Comparative analyses were performed with a Cox regression model using the weighted data. Analysis of perioperative complications was performed in the total cohort with logistic regression and adjustment using the same propensity weighting methods. A secondary analysis was performed comparing those who received concurrent AC and aspirin (ASA) therapy (ACASA) with those receiving ASA alone. To isolate the comparative effect of ACASA compared with ASA alone, patients receiving P2Y 12 antagonists were excluded from these groups. This secondary analysis used the same inverse propensity-weighted procedure as the primary analysis to balance characteristics between the two treatment groups. Additional exploratory analyses were performed according to type of conduit and distal target for the AC/non-AC comparison. Analyses based on conduit type were performed on those undergoing bypass with single-segment vein, NSV, and prosthetic conduits. Analyses based on both conduit type and distal target were performed on those with a prosthetic conduit to a below-knee popliteal target, an NSV conduit to a below-knee popliteal target, and an NSV conduit to an infrapopliteal target (defined as tibial, ankle, or foot artery). To assess for any bias due to the method of analysis, sensitivity analyses were performed using both multivariate Cox regression and logistic regression with binary primary patency. Variables for the multivariate regression models were selected using a combination of backward selection and forced inclusion of variables deemed to be clinically important. Two-sample t-test, Fisher exact test, c 2 test, Wilcoxon rank-sum test, and Kruskal-Wallis test were used for unadjusted comparisons between the AC and non-AC cohorts where appropriate. Normality was assessed where applicable using histogram plots. Unadjusted primary patency was estimated using the Kaplan-Meier method. Clustered standard errors were used for all regression analyses to account for the effect of multiple operations on the same patient. An a correction for multiple comparisons was not implemented for the exploratory analyses as their results were expected to be hypothesis generating rather than for purposes of causal inference.
RESULTS
We identified 23,242 infrainguinal bypass operations from 2003 to 2014 in the VQI database. We excluded 7713 who did not undergo bypass from an above-knee to a below-knee target and 7953 missing follow-up information; 7576 bypasses in 7214 patients were included in the study.
The mean age of the overall cohort was 67.5 6 11.2 years, and the majority were male (n ¼ 5292 [69.9%]). The majority of bypasses were performed for critical limb ischemia (n ¼ 4703 [62.1%]). The majority of patients did not receive postoperative AC (n ¼ 5411 [71%]). The median follow-up time for the cohort was 363 days (interquartile range [IQR] . 308-425), and the overall primary patency at 1 year was 71%.
In an unadjusted comparison of the AC and non-AC groups, those receiving AC were significantly older, with more chronic disease, higher rates of previous vascular procedures (Table I) , and higher rates of ipsilateral lower extremity vascular intervention, and they were more likely to be undergoing bypass for critical limb or acute limb ischemia (Table II) . As expected, the AC group had a significantly higher use of prosthetic and spliced vein conduits and vein cuff adjuncts, whereas the non-AC group had a higher rate of concurrent femoral endarterectomy. Unadjusted perioperative wound complications and need for transfusion were significantly higher in the AC group (Table III) . The median follow-up time was 365 days (IQR, 311-428) for the AC group and 358 days (IQR, 302-415) for the non-AC group. The unadjusted primary patency was 66.9% 6 1.2% for the AC group and 72.4% 6 0.7% for the non-AC group at 1 year (P < .001). We identified 4182 patients for inclusion in the ACASA/ ASA comparison; 31.6% received ACASA, and 68.4% received ASA. Similar to the AC/non-AC comparison, the ACASA group was significantly older, had a higher proportion of women, and had higher rates of chronic disease and previous intervention for peripheral vascular disease in unadjusted analysis (Table I ). The median follow-up time was 365 days (IQR, 311-425) for the ACASA group and 358 days (IQR, 302-414) for the ASA group. The unadjusted primary patency was 68.0% 6 1.4% for the ACASA group and 74.3% 6 0.9% for the ASA group at 1 year (P < .001).
Propensity-weighted analysis of AC compared with non-AC showed no significant differences in the hazard of primary patency loss (hazard ratio [HR], 0.98; 95% confidence interval [CI], 0.86-1.11; P ¼ .8). There was also no significant difference in amputation-free survival (HR, 1.09; 95% CI, 0.99-1.22; P ¼ .1). Comparison of the weighted cohorts using standardized differences showed adequate balance. Propensity-weighted analysis comparing ACASA with ASA likewise did not show a significant difference between groups for primary patency (HR, 1.04; 95% CI, 0.91-1.20; P ¼ .5) or amputation-free survival (HR, 1.11; 95% CI, 0.98-1.27; P ¼ .1). Further post hoc exploratory analysis of different conduit and below-knee or infrapopliteal targets showed trends toward improvement of primary patency (Fig 1) in those with a prosthetic conduit receiving AC (compared with non-AC: HR, 0.85; 95% CI, 0.80-1.02; P ¼ .09) or ACASA (compared with ASA: HR, 0.83; 95% CI, 0.66-1.03; P ¼ .09) and in those receiving AC with an NSV bypass to a below-knee popliteal artery target (HR, 0.78; 95% CI, 0.6-1.01; P ¼ .06). Analysis of propensity-weighted secondary patency similarly did not demonstrate a difference overall in either the AC/non-AC or ACASA/ASA comparisons. In subsequent exploratory analyses, however, AC and ACASA demonstrated statistically significant benefit for secondary patency in the prosthetic subgroup overall as well as in the prosthetic to infrapopliteal bypass subgroup (Fig 2) . Sensitivity analysis did not demonstrate any effect of AC on primary patency in a standard multivariate Cox regression model (Supplementary Table II , online only). Further sensitivity analysis using propensity-weighted logistic regression with a binary outcome at 1 year also supported the findings of the time-to-event analysis, failing to demonstrate a significant effect of AC on primary patency (odds ratio [OR], 0.95; 95% CI, 0.83-1.08; P ¼ .4) and showing a benefit for AC on secondary patency in the prosthetic subgroup (OR, 0.71; 95% CI, 0.55-0.92; P ¼ .01) and the prosthetic to infrapopliteal group (OR, 0.63; 95% CI, 0.42-0.93; P ¼ .02).
Propensity-weighted analysis of perioperative complications in the entire cohort showed that those receiving AC carried significantly higher odds of postoperative wound complication (OR, 1.34; 95% CI, 1.11-1.61; P ¼ .002). There was no statistically significant effect of AC on the odds of postoperative transfusion (OR, 1.03; 95% CI, 0.92-1.15), 
DISCUSSION
Infrainguinal bypass surgery continues to be needed in the treatment of lower extremity peripheral vascular disease. Despite the proliferation, success, and utility of endovascular techniques, bypass surgery continues to remain a recognized treatment for those with multilevel disease or those with no endovascular options. 1, 2 Practitioners have traditionally used antiplatelet and AC therapy to prolong patency and to improve durability of infrainguinal bypass grafts. Although antiplatelet agents have been shown to offer some improvement over no therapy, 10 especially in prosthetic grafts, 11 the data regarding therapeutic AC remain conflicting. Our study of 7576 bypass procedures in the VQI data set showed that those receiving postoperative AC were patients with more comorbidities undergoing more difficult "high-risk" procedures. They tended to be older and with more chronic disease; they were also more likely to have an indication of critical limb or acute ischemia and had higher rates of previous ipsilateral intervention. From an operative standpoint, those receiving AC on discharge had higher rates of distal rather than below-knee target, were less likely to have a single-segment-vein conduit, and were more likely to receive other operative adjuncts such as a vein cuff or sequential grafting. This suggests that practitioners are likely to use AC as an adjunct for patients they believe to be at higher risk for bypass thrombosis or occlusion. Although this assumption has served as the premise of previous randomized trials, 12 few studies have documented the practical characteristics of such a realworld cohort. 13 Our study did not demonstrate a significant difference in overall primary patency, secondary patency, or amputation-free survival in those receiving AC compared with non-AC at 1-year follow-up in a propensity-weighted cohort. Literature support for this result is conflicting, with equal numbers of randomized trials finding benefit 12, 14 or no difference. 15, 16 Further complicating synthesis of the data is the heterogeneity among trial designs. [3] [4] [5] Studies by Kretschmer 14 and Sarac et al 12 found evidence for superiority of AC, but both trials enrolled small samples, and the inclusion of only autologous vein conduits limits their generalizability. The larger Dutch Bypass Oral Anticoagulants or Aspirin [BOA] 15 and Veterans Affairs 16, 17 studies, in contrast, did not show an overall significant benefit for the use of AC. The BOA study, in particular, was limited by a high international normalized ratio target (3.5-4) and low patient compliance in the warfarin arm, with nearly half of patients failing to maintain a consistent therapeutic level of AC. We similarly did not find a significant difference in any end point for those receiving ACASA compared with ASA. Previous studies have demonstrated significant overall improvements for patients treated with ASA compared with no therapy or placebo, 10,11 especially for prosthetic bypass grafts. This has led to recommendations by the Society for Vascular Surgery 1 for the use of ASA after all peripheral bypasses if suitable, and indeed a high rate of ASA use was documented in our data. However, no consensus exists for the concurrent use of ASA in conjunction with anticoagulant therapy, as many randomized trials evaluating AC did so without mandating concurrent ASA therapy. Sarac et al 12 and the larger Veterans Affairs trial 16, 17 both used a combination of warfarin and ASA compared with ASA alone, but with opposing results. Monaco et al 18 showed an improvement in graft patency with warfarin in combination with clopidogrel compared with dual antiplatelet therapy alone but at the expense of a significantly higher hemorrhagic complication rate with the oral AC arm. Despite this favorable effect, use of clopidogrel in conjunction with oral anticoagulants for bypass grafts remains low in the general population as demonstrated in our study. Because of the conflicting nature of existing data and the nonsignificance of our results, it remains difficult to conclusively recommend the use of AC to improve bypass graft patency. Our exploratory analyses showed a trend toward improvement of primary patency and a significant improvement in secondary patency with AC, or AC in combination with ASA, in prosthetic bypass grafts. The effect of anticoagulants on prosthetic grafts has been analyzed in several previous studies, also with conflicting results. The Veterans Affairs trial 16, 17 found a significant benefit for AC in a subpopulation of 373 patients with prosthetic bypass grafts (relative risk, 0.62). In contrast, the 858 patients in the BOA study subgroup 15 did not demonstrate any benefit for AC; in fact, ASA alone significantly improved the risk compared with AC, although this conclusion is tempered by the inability of a large proportion of patients in the study to maintain a consistent level of therapeutic AC. Consensus for treatment in this subpopulation is mixed, with many guidelines 1,2,10 instead recommending dual antiplatelet therapy with ASA and a P2Y 12 inhibitor on the basis, in part, of favorable data from the Clopidogrel and Acetylsalicylic Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) study 19 without a strong recommendation for or against the use of AC. Our study also found primary patency improvement with AC in a subpopulation undergoing bypass to the below-knee popliteal artery with an NSV bypass graft as well as secondary patency improvement in prosthetic grafts especially to an infrapopliteal target. There may be a benefit to AC in improving the secondary patency of infrainguinal prosthetic grafts, and this should be considered even after correction of anatomic defects that may have led to bypass failure. However, these subpopulations have not been studied in a randomized trial, and as they may represent a set of patients at high risk for graft failure, this may be a potential area for future research.
Our results also showed significantly higher odds of perioperative wound complications but not of postoperative stroke, myocardial infarction, or need for transfusion in the AC group. These increases in wound complications have been previously suggested by Sarac et al, who showed a significantly higher rate of incisional hematoma requiring evacuation in anticoagulated patients, 12 and by Nguyen et al, who found a significant association of any wound complication with AC in a post hoc analysis of data from the Project of Ex-Vivo vein graft Engineering via Transfection III [PREVENT III] trial. 20 However, other trials have not demonstrated a similar effect in the perioperative period. 15, 16 The increased risk of wound complications in these patients should be taken into account when a determination for postoperative AC is made.
There are several limitations to our study. Because this is a retrospective analysis without randomization, it is still subject to selection bias despite statistical adjustment. The 1-year minimum follow-up time for VQI data does not allow study of longer term results. Previous randomized studies of infrainguinal bypass grafts have demonstrated differences in long-term (2þ years) outcome despite no difference at a 1-year time point, 6 emphasizing the limitations of determining efficacy at only 1 year in our study. Follow-up compliance in the VQI data sets is often limited as evidenced by the relatively high percentage of patients excluded in our study because of missing follow-up information. Although the VQI comprises procedure-and disease-specific information, certain data elements may not be collected in specific data sets, such as the presence of distal runoff or long-term hemorrhagic complications. These unmeasured confounders as well as the possibility of a small effect size of AC in many of the studied populations may lead to a false association between the treatment and outcome. The assessment of patency rates may also be limited by variability of follow-up and surveillance protocols among participating centers. The accuracy of patency estimates derived from interventions or surveillance studies reported in the VQI is difficult to validate. Finally, we planned multiple exploratory analyses examining multiple subpopulations because of the heterogeneous nature of previous studies. Because these analyses were not for the purposes of causal inference, a adjustment was not performed; however, the probability of type I error is still increased with multiple successive comparisons. Despite these limitations, we believe that this study provides a series of informative analyses using midterm results from a real-world disease-and procedure-specific data set that can be used to guide clinical decision-making and to inform further study.
CONCLUSIONS
Overall, our study did not demonstrate any significant differences in primary patency between AC and no-AC, or in AC concurrently with ASA compared with ASA alone, in midterm follow-up of patients with bypass graft surgery to a below-knee target in propensity-weighted cohorts while carrying higher odds of postoperative wound complications. Exploratory analyses identified a significant secondary patency benefit for prosthetic bypasses, especially to an infrapopliteal target; this subpopulation may benefit from AC to improve patency and should serve as a target population for future prospective studies.
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